Xencor XNCR 深 滬
等待開盤 10-22 09:30:00 美东时间
14.51
-0.560
-3.72%
華盛通- 最 高15.34
- 今 開15.07
- 成交量 115.57万股
- 最 低 14.275
- 昨 收 15.07
- 總市值 10.35亿
- 52周最高 27.24
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 6.92
- 委 比 -56.90%
- 總股本 7132.30万
- 歷史最高 58.345
- 量 比 0.50
- 振 幅 7.07%
- 歷史最低 5.75
- 每 手 1
- 風險率 6.17%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – MIT and Harvard scientists recently created...
10-17 21:50
Candel Therapeutics signs $130M term loan facility with Trinity Capital
Candel Therapeutics (NASDAQ:CADL) announced on Tuesday that it has entered into a five-year, $130M term loan facility with Trinity Capital. The facility included four tranches, starting with the first...
10-15 02:56
Xencor To Present Initial Results From Ongoing Phase 1 Dose-Escalation Study Of Xmab819 In Patients With ccRCC At AACR-NCI-EORTC Conference 2025
-- Management to host webcast and conference call on Friday, October 24, 2025 --Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and
10-15 00:47
超142亿，3款自免管线出海！
（来源：动脉新医药） 10月8日，诺诚健华和Zenas联合宣布，双方达成重磅授权许可协议，Zenas将获得奥布替尼在多发性硬化领域的全球开发和商业化权益，以及奥...
10-09 13:09
美股大行评级 | 潜在涨幅4347.41%！Ascendiant Capital上调PAVmed目标价至20美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持PAVmed"买入"评级，目标价从19美元升至20美元；Ascendiant Capital：维持Plus Therapeutics"买入"评级，目标价从20.5美元升至21美元
10-07 15:04
Cantor Fitzgerald Assumes Xencor at Overweight, Announces Price Target of $40
Cantor Fitzgerald analyst Steve Seedhouse assumes Xencor (NASDAQ:XNCR) with a Overweight rating and announces Price Target of $40.
10-06 21:30
Xencor (XNCR) Receives a Sell from Barclays
Barclays analyst Etzer Darout initiated coverage with a Sell rating on Xencor o...
09-19 16:15
【膜杰作】STEAP：二十年磨一剑，或为实体瘤治疗的下一突破口
（来源：ACROBiosystems官方） 转自：ACROBiosystems官方 在全球抗癌药物研发中，细胞表面靶点始终占据核心地位。STEAP（前列腺六次跨...
09-17 17:43
二代IO争霸，暗藏哪些玄机？
（来源：药剂Talks） 下一代肿瘤“药王”，极有可能诞生于PD-(L)1 Plus领域。 以K药为代表的PD-1单抗，开启了一代IO（肿瘤免疫治疗）时代，但...
09-04 07:52
Beyond The Numbers: 4 Analysts Discuss Xencor Stock
Ratings for Xencor (NASDAQ:XNCR) were provided by 4 analysts in the past three ...
09-03 05:00
